Integrating a multimodal lifestyle intervention with medical food in prodromal Alzheimer's disease: the MIND-AD

Humans Alzheimer Disease / therapy Female Male Aged Middle Aged Life Style Aged, 80 and over Prodromal Symptoms Combined Modality Therapy / methods Exercise / physiology Cognitive Dysfunction / therapy
Adherence Alzheimer’s disease Lifestyle intervention Medical food Multimodal intervention Prevention Randomized controlled trial

Journal

Alzheimer's research & therapy
ISSN: 1758-9193
Titre abrégé: Alzheimers Res Ther
Pays: England
ID NLM: 101511643

Informations de publication

Date de publication:
30 May 2024
Historique:
received: 18 02 2024
accepted: 27 04 2024
medline: 30 5 2024
pubmed: 30 5 2024
entrez: 29 5 2024
Statut: epublish

Résumé

The Finnish Geriatric Intervention Study to Prevent Cognitive Impairment and Disability (FINGER) showed cognitive benefits from a multidomain lifestyle intervention in at-risk older people. The LipiDiDiet trial highlighted benefits of medical food in prodromal Alzheimer's disease (AD). However, the feasibility and impact of multimodal interventions combining lifestyle with medical food in prodromal AD is unclear. MIND-AD During September 2017-May 2019, 93 individuals were randomized (32 lifestyle intervention, 31 lifestyle + medical food, and 30 control group). Overall recruitment rate was 76.2% (64.8% during the first 6 months). Overall 6-month retention rate was 91.4% (lifestyle intervention 87.5%; lifestyle + medical food 90.3%; control 96.7%). Domain-specific adherence in the lifestyle intervention group was 71.9% to cognitive training, 78.1% exercise, 68.8% nutritional guidance, and 81.3% vascular risk management; and in the lifestyle + medical food group, 90.3% to cognitive training, 87.1% exercise, 80.7% nutritional guidance, 87.1% vascular risk management, and 87.1% medical food. Compared with control, both intervention arms showed healthy diet improvements (β The multidomain lifestyle intervention, alone or combined with medical food, had good feasibility and adherence in prodromal AD. Longer-term cognitive and other health benefits should be further investigated in a larger-scale trial. ClinicalTrials.gov NCT03249688.

Sections du résumé

BACKGROUND BACKGROUND
The Finnish Geriatric Intervention Study to Prevent Cognitive Impairment and Disability (FINGER) showed cognitive benefits from a multidomain lifestyle intervention in at-risk older people. The LipiDiDiet trial highlighted benefits of medical food in prodromal Alzheimer's disease (AD). However, the feasibility and impact of multimodal interventions combining lifestyle with medical food in prodromal AD is unclear.
METHODS METHODS
MIND-AD
RESULTS RESULTS
During September 2017-May 2019, 93 individuals were randomized (32 lifestyle intervention, 31 lifestyle + medical food, and 30 control group). Overall recruitment rate was 76.2% (64.8% during the first 6 months). Overall 6-month retention rate was 91.4% (lifestyle intervention 87.5%; lifestyle + medical food 90.3%; control 96.7%). Domain-specific adherence in the lifestyle intervention group was 71.9% to cognitive training, 78.1% exercise, 68.8% nutritional guidance, and 81.3% vascular risk management; and in the lifestyle + medical food group, 90.3% to cognitive training, 87.1% exercise, 80.7% nutritional guidance, 87.1% vascular risk management, and 87.1% medical food. Compared with control, both intervention arms showed healthy diet improvements (β
CONCLUSIONS CONCLUSIONS
The multidomain lifestyle intervention, alone or combined with medical food, had good feasibility and adherence in prodromal AD. Longer-term cognitive and other health benefits should be further investigated in a larger-scale trial.
TRIAL REGISTRATION BACKGROUND
ClinicalTrials.gov NCT03249688.

Identifiants

DOI: 10.1186/s13195-024-01468-x PMID: 38812047
pubmed: 38812047
doi: 10.1186/s13195-024-01468-x
pii: 10.1186/s13195-024-01468-x
doi:

Banques de données

ClinicalTrials.gov
['NCT03249688']

Types de publication

Journal Article Randomized Controlled Trial Multicenter Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

118

Subventions

Organisme : European Research Council grant
ID : 804371

Informations de copyright

© 2024. The Author(s).

Références

Livingston G, Huntley J, Sommerlad A, Ames D, Ballard C, Banerjee S, et al. Dementia prevention, intervention, and care: 2020 report of the Lancet Commission. Lancet. 2020;396(10248):413–46.
doi: 10.1016/S0140-6736(20)30367-6 pubmed: 32738937 pmcid: 7392084
Dubois B, Feldman HH, Jacova C, Dekosky ST, Barberger-Gateau P, Cummings J, et al. Research criteria for the diagnosis of Alzheimer’s disease: revising the NINCDS-ADRDA criteria. Lancet Neurol. 2007;6(8):734–46.
doi: 10.1016/S1474-4422(07)70178-3 pubmed: 17616482
Jack CR Jr, Bennett DA, Blennow K, Carrillo MC, Dunn B, Haeberlein SB, et al. NIA-AA Research Framework: Toward a biological definition of Alzheimer’s disease. Alzheimers Dement. 2018;14(4):535–62.
doi: 10.1016/j.jalz.2018.02.018 pubmed: 29653606
Ashton NJ, Janelidze S, Mattsson-Carlgren N, Binette AP, Strandberg O, Brum WS, et al. Differential roles of Abeta42/40, p-tau231 and p-tau217 for Alzheimer’s trial selection and disease monitoring. Nat Med. 2022;28(12):2555–62.
doi: 10.1038/s41591-022-02074-w pubmed: 36456833 pmcid: 9800279
Schneider LS, Mangialasche F, Andreasen N, Feldman H, Giacobini E, Jones R, et al. Clinical trials and late-stage drug development for Alzheimer’s disease: an appraisal from 1984 to 2014. J Intern Med. 2014;275(3):251–83.
doi: 10.1111/joim.12191 pubmed: 24605808 pmcid: 3956752
van Dyck CH, Swanson CJ, Aisen P, Bateman RJ, Chen C, Gee M, et al. Lecanemab in Early Alzheimer’s Disease. N Engl J Med. 2023;388(1):9–21.
doi: 10.1056/NEJMoa2212948 pubmed: 36449413
Solomon A, Stephen R, Altomare D, Carrera E, Frisoni GB, Kulmala J, et al. Multidomain interventions: state-of-the-art and future directions for protocols to implement precision dementia risk reduction . A user manual for Brain Health Services-part 4 of 6. Alzheimers Res Ther. 2021;13(1):171.
doi: 10.1186/s13195-021-00875-8 pubmed: 34635167 pmcid: 8507202
Scheltens P, De Strooper B, Kivipelto M, Holstege H, Chételat G, Teunissen CE, et al. Alzheimer’s disease. Lancet. 2021;397(10284):1577–90.
doi: 10.1016/S0140-6736(20)32205-4 pubmed: 33667416 pmcid: 8354300
Lehtisalo J, Ngandu T, Valve P, Antikainen R, Laatikainen T, Strandberg T, et al. Nutrient intake and dietary changes during a 2-year multi-domain lifestyle intervention among older adults: secondary analysis of the Finnish Geriatric Intervention Study to Prevent Cognitive Impairment and Disability (FINGER) randomised controlled trial. Br J Nutr. 2017;118(4):291–302.
doi: 10.1017/S0007114517001982 pubmed: 28875868
Soininen H, Solomon A, Visser PJ, Hendrix SB, Blennow K, Kivipelto M, et al. 36-month LipiDiDiet multinutrient clinical trial in prodromal Alzheimer’s disease. Alzheimers Dement. 2021;17(1):29–40.
doi: 10.1002/alz.12172 pubmed: 32920957
Ngandu T, Lehtisalo J, Solomon A, Levalahti E, Ahtiluoto S, Antikainen R, et al. A 2 year multidomain intervention of diet, exercise, cognitive training, and vascular risk monitoring versus control to prevent cognitive decline in at-risk elderly people (FINGER): a randomised controlled trial. Lancet. 2015;385(9984):2255–63.
doi: 10.1016/S0140-6736(15)60461-5 pubmed: 25771249
Neuvonen E, Lehtisalo J, Solomon A, Antikainen R, Havulinna S, Hänninen T, et al. Psychosocial determinants for adherence to a healthy lifestyle and intervention participation in the FINGER trial: an exploratory analysis of a randomised clinical trial. Aging Clin Exp Res. 2022;34(8):1793–805.
doi: 10.1007/s40520-022-02088-x pubmed: 35182352 pmcid: 9283154
Rosenberg A, Ngandu T, Rusanen M, Antikainen R, Backman L, Havulinna S, et al. Multidomain lifestyle intervention benefits a large elderly population at risk for cognitive decline and dementia regardless of baseline characteristics: The FINGER trial. Alzheimers Dement. 2018;14(3):263–70.
doi: 10.1016/j.jalz.2017.09.006 pubmed: 29055814
Lehtisalo J, Rusanen M, Solomon A, Antikainen R, Laatikainen T, Peltonen M, et al. Effect of a multi-domain lifestyle intervention on cardiovascular risk in older people: the FINGER trial. Eur Heart J. 2022;43(21):2054–61.
doi: 10.1093/eurheartj/ehab922 pubmed: 35051281 pmcid: 9156384
Sindi S, Thunborg C, Rosenberg A, Andersen P, Andrieu S, Broersen LM, et al. Multimodal Preventive Trial for Alzheimer’s Disease: MIND-ADmini Pilot Trial Study Design and Progress. J Prev Alzheimers Dis. 2022;9(1):30–9.
pubmed: 35098971 pmcid: 8783958
Dubois B, Feldman HH, Jacova C, Hampel H, Molinuevo JL, Blennow K, et al. Advancing research diagnostic criteria for Alzheimer’s disease: the IWG-2 criteria. Lancet Neurol. 2014;13(6):614–29.
doi: 10.1016/S1474-4422(14)70090-0 pubmed: 24849862
Nordic Nutrition Recommendations 2012 : Integrating nutrition and physical activity [Internet]. 5th ed. Copenhagen: Nordisk Ministerråd; 2014. 627 p. (Nord).
World Health Organisation. Global action plan on physical activity 2018–2030: more active people for a healthier world Geneva 2018 [updated 1 June 2018. Available from: https://www.who.int/publications-detail/global-action-plan-on-physical-activity-2018%E2%80%932030 .
Nelson ME, Rejeski WJ, Blair SN, Duncan PW, Judge JO, King AC, et al. Physical activity and public health in older adults: recommendation from the American College of Sports Medicine and the American Heart Association. Med Sci Sports Exerc. 2007;39(8):1435–45.
doi: 10.1249/mss.0b013e3180616aa2 pubmed: 17762378
Hakola L, Hassinen M, Komulainen P, Lakka TA, Savonen K, Rauramaa R. Correlates of low physical activity levels in aging men and women: the DR’s EXTRA Study. J Aging Phys Act. 2015;23(2):247–55.
doi: 10.1123/japa.2013-0169 pubmed: 24911019
Schröder H, Fitó M, Estruch R, Martínez-González MA, Corella D, Salas-Salvadó J, et al. A short screener is valid for assessing Mediterranean diet adherence among older Spanish men and women. J Nutr. 2011;141(6):1140–5.
doi: 10.3945/jn.110.135566 pubmed: 21508208
Vartiainen E, Laatikainen T, Peltonen M, Puska P. Predicting Coronary Heart Disease and Stroke: The FINRISK Calculator. Glob Heart. 2016;11(2):213–6.
doi: 10.1016/j.gheart.2016.04.007 pubmed: 27242089
Ngandu T, Lehtisalo J, Korkki S, Solomon A, Coley N, Antikainen R, et al. The effect of adherence on cognition in a multidomain lifestyle intervention (FINGER). Alzheimers Dement. 2022;18(7):1325–34.
doi: 10.1002/alz.12492 pubmed: 34668644
Morris JC. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology. 1993;43(11):2412–4.
doi: 10.1212/WNL.43.11.2412-a pubmed: 8232972
Hughes CP, Berg L, Danziger WL, Coben LA, Martin RL. A new clinical scale for the staging of dementia. Br J Psychiatry. 1982;140:566–72.
doi: 10.1192/bjp.140.6.566 pubmed: 7104545
French B, Shotwell MS. Regression Models for Ordinal Outcomes. JAMA. 2022;328(8):772–3.
doi: 10.1001/jama.2022.12104 pubmed: 35925592
van Dyck CH, Swanson CJ, Aisen P, Bateman RJ, Chen C, Gee M, et al. Lecanemab in Early Alzheimer’s Disease. N Engl J Med. 2022;388(1):9–21.
doi: 10.1056/NEJMoa2212948 pubmed: 36449413
Rosenberg A, Ohlund-Wistbacka U, Hall A, Bonnard A, Hagman G, Ryden M, et al. beta-Amyloid, Tau, Neurodegeneration Classification and Eligibility for Anti-amyloid Treatment in a Memory Clinic Population. Neurology. 2022;99(19):e2102–13.
doi: 10.1212/WNL.0000000000201043 pubmed: 36130840 pmcid: 9651451
Muth AK, Park SQ. The impact of dietary macronutrient intake on cognitive function and the brain. Clin Nutr. 2021;40(6):3999–4010.
doi: 10.1016/j.clnu.2021.04.043 pubmed: 34139473
Caldwell CC, Yao J, Brinton RD. Targeting the prodromal stage of Alzheimer’s disease: bioenergetic and mitochondrial opportunities. Neurotherapeutics. 2015;12(1):66–80.
doi: 10.1007/s13311-014-0324-8 pubmed: 25534394
Coley N, Ngandu T, Lehtisalo J, Soininen H, Vellas B, Richard E, et al. Adherence to multidomain interventions for dementia prevention: Data from the FINGER and MAPT trials. Alzheimers Dement. 2019;15(6):729–41.
doi: 10.1016/j.jalz.2019.03.005 pubmed: 31047857
Chew KA, Xu X, Siongco P, Villaraza S, Phua AKS, Wong ZX, et al. SINgapore GERiatric intervention study to reduce physical frailty and cognitive decline (SINGER)-pilot: A feasibility study. Alzheimers Dement (N Y). 2021;7(1): e12141.
doi: 10.1002/trc2.12141 pubmed: 33748399
Lee EH, Kim GH, Park HK, Kang HJ, Park YK, Lee HA, et al. Effects of the multidomain intervention with nutritional supplements on cognition and gut microbiome in early symptomatic Alzheimer’s disease: a randomized controlled trial. Front Aging Neurosci. 2023;15:1266955.
doi: 10.3389/fnagi.2023.1266955 pubmed: 38020771 pmcid: 10652389
Xu Z, Zhang D, Lee ATC, Sit RWS, Wong C, Lee EKP, et al. A pilot feasibility randomized controlled trial on combining mind-body physical exercise, cognitive training, and nurse-led risk factor modification to reduce cognitive decline among older adults with mild cognitive impairment in primary care. PeerJ. 2020;8: e9845.
doi: 10.7717/peerj.9845 pubmed: 33194354 pmcid: 7482623
Akenine U, Thunborg C, Kivipelto M, Fallahpour M. Experiences of Participation in a Multimodal Preventive Trial MIND-ADmini Among Persons with Prodromal Alzheimer’s Disease: A Qualitative Study. J Multidiscip Healthc. 2021;15:219–34.
doi: 10.2147/JMDH.S345607
Rosenberg A, Mangialasche F, Ngandu T, Solomon A, Kivipelto M. Multidomain Interventions to Prevent Cognitive Impairment, Alzheimer’s Disease, and Dementia: From FINGER to World-Wide FINGERS. J Prev Alzheimers Dis. 2020;7(1):29–36.
pubmed: 32010923

Auteurs

Charlotta Thunborg (C)

Division of Clinical Geriatrics, Department of Neurobiology, Care Sciences and Society, Center for Alzheimer Research QA32, Karolinska Institute, Karolinska Vägen 37 A, Solna, 171 64, Sweden.
Theme Inflammation and Aging, Karolinska University Hospital, Karolinska Vägen 37 A, Solna, Stockholm, 171 64, Sweden.
Department of Caring Sciences, Faculty of Health and Occupational Studies, Gävle, 801 76, Sweden.

Rui Wang (R)

Division of Clinical Geriatrics, Department of Neurobiology, Care Sciences and Society, Center for Alzheimer Research QA32, Karolinska Institute, Karolinska Vägen 37 A, Solna, 171 64, Sweden.
Department of Physical Activity and Health, the Swedish School of Sport and Health Sciences, Stockholm, SE-114 86, Sweden.
Wisconsin Alzheimer's Disease Research Center, School of Medicine and Public Health, University of Wisconsin, 600 Highland Ave J5/1 Mezzanine, Madison, WI, 53792, USA.

Anna Rosenberg (A)

Division of Clinical Geriatrics, Department of Neurobiology, Care Sciences and Society, Center for Alzheimer Research QA32, Karolinska Institute, Karolinska Vägen 37 A, Solna, 171 64, Sweden.
Department of Neurology, Institute of Clinical Medicine, University of Eastern Finland, Yliopistonranta 8, Kuopio, 70210, Finland.

Shireen Sindi (S)

Division of Clinical Geriatrics, Department of Neurobiology, Care Sciences and Society, Center for Alzheimer Research QA32, Karolinska Institute, Karolinska Vägen 37 A, Solna, 171 64, Sweden.
The Ageing Epidemiology (AGE) Research Unit, School of Public Health, Imperial College London, St Mary's Hospital, Norfolk Place, London, W2 1PG, UK.

Pia Andersen (P)

Division of Clinical Geriatrics, Department of Neurobiology, Care Sciences and Society, Center for Alzheimer Research QA32, Karolinska Institute, Karolinska Vägen 37 A, Solna, 171 64, Sweden.
Theme Inflammation and Aging, Karolinska University Hospital, Karolinska Vägen 37 A, Solna, Stockholm, 171 64, Sweden.

Sandrine Andrieu (S)

Department of Clinical Epidemiology and Public Health, CHU de Toulouse, and Aging Research Team, CERPOP Inserm UMR 1295, Jules Guesde, Toulouse, 31000, France.
IHU HealthAge, Toulouse, 31059, France.

Laus M Broersen (LM)

Danone Nutricia Research, Utrecht, Netherlands.

Nicola Coley (N)

Department of Clinical Epidemiology and Public Health, CHU de Toulouse, and Aging Research Team, CERPOP Inserm UMR 1295, Jules Guesde, Toulouse, 31000, France.
IHU HealthAge, Toulouse, 31059, France.

Celine Couderc (C)

Department of Clinical Epidemiology and Public Health, CHU de Toulouse, and Aging Research Team, CERPOP Inserm UMR 1295, Jules Guesde, Toulouse, 31000, France.

Celine Z Duval (CZ)

German Institute for Dementia Prevention (DIDP), Saarland University, Homburg, 66424, Germany.
Institute of General Practice, Goethe University Frankfurt a.M, Frankfurt, 60590, Germany.

Gerd Faxen-Irving (G)

Division of Clinical Geriatrics, Department of Neurobiology, Care Sciences and Society, Center for Alzheimer Research QA32, Karolinska Institute, Karolinska Vägen 37 A, Solna, 171 64, Sweden.

Göran Hagman (G)

Theme Inflammation and Aging, Karolinska University Hospital, Karolinska Vägen 37 A, Solna, Stockholm, 171 64, Sweden.

Merja Hallikainen (M)

The Ageing Epidemiology (AGE) Research Unit, School of Public Health, Imperial College London, St Mary's Hospital, Norfolk Place, London, W2 1PG, UK.

Krister Håkansson (K)

Division of Clinical Geriatrics, Department of Neurobiology, Care Sciences and Society, Center for Alzheimer Research QA32, Karolinska Institute, Karolinska Vägen 37 A, Solna, 171 64, Sweden.
Theme Inflammation and Aging, Karolinska University Hospital, Karolinska Vägen 37 A, Solna, Stockholm, 171 64, Sweden.
Stockholm Gerontology Research Center, Tomtebodavägen 18a, Solna, 171 65, Sweden.

Eija Kekkonen (E)

The Ageing Epidemiology (AGE) Research Unit, School of Public Health, Imperial College London, St Mary's Hospital, Norfolk Place, London, W2 1PG, UK.

Jenni Lehtisalo (J)

The Ageing Epidemiology (AGE) Research Unit, School of Public Health, Imperial College London, St Mary's Hospital, Norfolk Place, London, W2 1PG, UK.
Population Health Unit, Department of Public Health and Welfare, Finnish Institute for Health and Welfare, Mannerheimintie 166, P.O. Box 30, Helsinki, Finland.

Nicholas Levak (N)

Division of Clinical Geriatrics, Department of Neurobiology, Care Sciences and Society, Center for Alzheimer Research QA32, Karolinska Institute, Karolinska Vägen 37 A, Solna, 171 64, Sweden.
Theme Inflammation and Aging, Karolinska University Hospital, Karolinska Vägen 37 A, Solna, Stockholm, 171 64, Sweden.

Francesca Mangialasche (F)

Division of Clinical Geriatrics, Department of Neurobiology, Care Sciences and Society, Center for Alzheimer Research QA32, Karolinska Institute, Karolinska Vägen 37 A, Solna, 171 64, Sweden.

Johannes Pantel (J)

German Institute for Dementia Prevention (DIDP), Saarland University, Homburg, 66424, Germany.
Institute of General Practice, Goethe University Frankfurt a.M, Frankfurt, 60590, Germany.

Anders Rydström (A)

Division of Clinical Geriatrics, Department of Neurobiology, Care Sciences and Society, Center for Alzheimer Research QA32, Karolinska Institute, Karolinska Vägen 37 A, Solna, 171 64, Sweden.

Anna Stigsdotter-Neely (A)

Department of Social and Psychological Studies, Karlstad University, Karlstad, 651 88, Sweden.
Engineering Psychology, Luleå University of Technology, Luleå, 971 87, Sweden.

Anders Wimo (A)

Division of Clinical Geriatrics, Department of Neurobiology, Care Sciences and Society, Center for Alzheimer Research QA32, Karolinska Institute, Karolinska Vägen 37 A, Solna, 171 64, Sweden.

Tiia Ngandu (T)

Population Health Unit, Department of Public Health and Welfare, Finnish Institute for Health and Welfare, Mannerheimintie 166, P.O. Box 30, Helsinki, Finland.

Hilkka Soininen (H)

The Ageing Epidemiology (AGE) Research Unit, School of Public Health, Imperial College London, St Mary's Hospital, Norfolk Place, London, W2 1PG, UK.

Tobias Hartmann (T)

German Institute for Dementia Prevention (DIDP), Saarland University, Homburg, 66424, Germany.
Department of Experimental Neurology, Medical Faculty, Saarland University, Homburg, 66424, Germany.

Alina Solomon (A)

Division of Clinical Geriatrics, Department of Neurobiology, Care Sciences and Society, Center for Alzheimer Research QA32, Karolinska Institute, Karolinska Vägen 37 A, Solna, 171 64, Sweden.
Department of Neurology, Institute of Clinical Medicine, University of Eastern Finland, Yliopistonranta 8, Kuopio, 70210, Finland.
The Ageing Epidemiology (AGE) Research Unit, School of Public Health, Imperial College London, St Mary's Hospital, Norfolk Place, London, W2 1PG, UK.

Miia Kivipelto (M)

Division of Clinical Geriatrics, Department of Neurobiology, Care Sciences and Society, Center for Alzheimer Research QA32, Karolinska Institute, Karolinska Vägen 37 A, Solna, 171 64, Sweden. miia.kivipelto@ki.se.
Theme Inflammation and Aging, Karolinska University Hospital, Karolinska Vägen 37 A, Solna, Stockholm, 171 64, Sweden. miia.kivipelto@ki.se.
Department of Neurology, Institute of Clinical Medicine, University of Eastern Finland, Yliopistonranta 8, Kuopio, 70210, Finland. miia.kivipelto@ki.se.
The Ageing Epidemiology (AGE) Research Unit, School of Public Health, Imperial College London, St Mary's Hospital, Norfolk Place, London, W2 1PG, UK. miia.kivipelto@ki.se.
Institute of Public Health and Clinical Nutrition, University of Eastern Finland, Yliopistonranta 8, Kuopio, 70210, Finland. miia.kivipelto@ki.se.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Integrating a multimodal lifestyle...
questionsmedicales.fr › Troubles mentaux › Troubles neurocognitifs › Démence › Maladie d'Alzheimer › Integrating a multimodal lifestyle...
questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Sujet âgé › Integrating a multimodal lifestyle...
questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Adulte d'âge moyen › Integrating a multimodal lifestyle...
questionsmedicales.fr › Comportement et mécanismes comportementaux › Mode de vie › Integrating a multimodal lifestyle...
questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Sujet âgé › Sujet âgé de 80 ans ou plus › Integrating a multimodal lifestyle...
questionsmedicales.fr › Diagnostic › Symptômes prodromiques › Integrating a multimodal lifestyle...
questionsmedicales.fr › Thérapeutique › Association thérapeutique › Integrating a multimodal lifestyle...
questionsmedicales.fr › Activités humaines › Exercice physique › Integrating a multimodal lifestyle...
questionsmedicales.fr › Troubles mentaux › Troubles neurocognitifs › Troubles de la cognition › Dysfonctionnement cognitif › Integrating a multimodal lifestyle...